Do you want to read an article? Please log in or register.
Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials
Asthma
RECOMMENDED
Related content
AsthmaCOPD
Pharmacokinetics of tiotropium administered by Respimat® in asthma patients: Analysis of pooled data from Phase II and III clinical trials
Pulm Pharmacol Ther.
Sharma A, Kerstjens HA, Aalbers R, Moroni-Zentgraf P, Weber B, Dahl R
doi: 10.1016/j.pupt.2016.12.003.
RECOMMENDED
Asthma
Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med
Busse WW, Wenzel SE, Casale TB, FitzGerald JM, Rice MS, Daizadeh N, Deniz Y, Patel N, Harel S, Rowe PJ, Graham NMH, O'Riordan T, Pavord ID
doi: 10.1016/S2213-2600(21)00124-7
Asthma
A novel endpoint for exacerbations in asthma to accelerate clinical development: a post-hoc analysis of randomised controlled trials
Urol Oncol.
Fuhlbrigge AL, Bengtsson T,
Peterson S, Jauhiainen A, Eriksson G, Da Silva CA, Johnson A, Sethi T, Locantore N, Tal-Singer R, Fagerås M
doi: 10.1016/j.urolonc.2017.04.010.
Fluticasone furoate/vilanterol once daily improves night-time awakenings in asthma patients with night symptoms; post-hoc analyses of three randomized controlled trials
J Asthma
Kerwin E, Barnes N, Gibbs M, Leather D, Forth R, Jacques L, Yates LJ
doi: 10.1080/02770903.
Asthma
Omalizumab versus Mepolizumab as add-on therapy in asthma patients not well controlled on at least an inhaled corticosteroid: A network meta-analysis
J Asthma.
Nachef Z, Krishnan A, Mashtare T, Zhuang T, Mador MJ
doi: 10.1080/
COMMENTED
Asthma
Dupilumab safety and efficacy in uncontrolled asthma: a systematic review and meta-analysis of randomized clinical trials
J Asthma.
Zayed Y, Kheiri B, Banifadel M, Hicks M, Aburahma A, Hamid K, Bachuwa G, Chandran A
doi: 10.1080/02770903.
RECOMMENDED
Asthma
Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA
Respir Res.
Albers FC, Papi A, Taillé C, Bratton DJ, Bradford ES, Yancey SW, Kwon N
doi: 10.1186/s12931-019-1134-7.
Asthma
Effect of a single day of increased as-needed budesonide-formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study
Lancet Respir Med.
O'Byrne PM, FitzGerald JM, Bateman ED, Barnes PJ, Zheng J, Gustafson P, Lamarca R, Puu M, Keen C, Alagappan VKT, Reddel HK
doi: 10.1016/S2213-2600(20)30416-1.
RECOMMENDED
Asthma
Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Med.
Albers FC, Licskai C, Chanez P, Bratton DJ, Bradford ES, Yancey SW, Kwon N, Quirce S
doi: 10.1016/j.rmed.2019.105806.